The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Enhancing metastatic pMMR colorectal cancer treatments
Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses standard treatment approaches based on RAF/BRAF mutations, for patients that have metastatic proficient mismatch repair (pMMR) colorectal cancer. Strategies to improve current treatments include selecting patients eligible for anti-EGFR monoclonal antibodies and integrating immune checkpoint inhibitors in future treatments. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
